Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Oncology Drug Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    ModifiedHawaii Medical Service Association (HMSA)Policy N/A

    Pharmacy Global Oncology

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs precertification and coverage of pharmacy-benefit oncology drugs and medical injectable or infusible drugs prescribed as part of an oncology regimen. The entire regimen may be covered when each drug meets the policy criteria and the member has no applicable exclusions.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyPharmacy Global Oncology
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJul 23, 2026
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain precertification for one or more agents in every prescribed oncology regimen before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history records addition of Lytgobi on 12/02/2022.

    The policy history records addition of Jaypirca and Orserdu on 02/10/2023.

    The policy history records addition of Akeega on 10/10/2023.

    The policy history records addition of Iwilfin and Ogsiveo on 04/18/2024.

    The policy history records addition of Ojemda on 05/17/2024.

    The policy history records addition of Truqap on 07/15/2024.

    The policy history records addition of generics-first criteria in an August 2024 off-cycle update.

    The policy history records addition of Voranigo on 08/15/2024 and Lazcluze on 09/10/2024.

    The policy history records addition of Danziten, Revuforj, and Itovebi on 12/16/2024.

    The policy history records addition of Imkeldi on 01/15/2025 and Gomekli on 02/28/2025.

    The policy history records addition of Romvimza on 03/23/2025.

    The policy history records addition of Avmapki, Ensacove, Ibtrozi, and nilotinib on 07/10/2025.

    The policy history records addition of Hernexeos and Modeyso on 08/26/2025.

    The policy history records addition of Phyrago and Inluriyo on 11/18/2025, followed by Hyrnuo and Komzifti on 12/23/2025.

    The policy history records addition of Lifyorli on 04/14/2026 and Cavhanza and Veppanu on 07/23/2026.

    The policy history records removal of HMSA pharmacy benefit manager co-branding on 09/05/2023.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInitial authorization period
    12 monthsAdditional reauthorization period
    FDA/NCCN I-IIAInitial authorization support
    RequiredUtilization-management requirement
    Generic trialBrand medication prerequisite
    No progressionReauthorization response finding

    Coverage Criteria

    Initial Therapy

    Authorization for 6 months may be granted when the member is prescribed a single agent or regimen supported by at least ONE of the following:

    ONE of

    • The prescribed single agent or regimen has an FDA-approved indication.
    • The prescribed single agent or regimen has a National Comprehensive Cancer Network (NCCN) category I or IIA recommendation.

    Reauthorization

    Approval for an additional 12 months may be granted when ALL of the following documentation requirements are met:

    ALL of the following

    • The member was previously approved for the drug or regimen by HMSA or HMSA's Pharmacy Benefit Manager.
    • A current oncology note documents the patient's response to treatment, showing no progression of disease.
    • Current imaging studies and other objective measures show no progression of disease when compared with previous results.

    Initial Approval When No Previous Authorization Exists

    Members with no previous authorization or precertification, including new members and members currently receiving treatment without prior authorization, must meet the criteria for initial approval in Section C.

    ALL of the following

    • The member meets the Initial Therapy criteria for authorization of 6 months.

    Brand Medication Exception

    Where applicable, a member must try and fail an A-rated generic equivalent before receiving the brand medication. Brand approval requires ALL of the following:

    ALL of the following

    • The patient failed treatment with the generic medication due to an intolerable adverse event, such as rash, nausea, or vomiting.
    • The adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information; that is, it was not a known adverse reaction for both the brand and generic medication.
    • ONE of the following documentation options

      • Specific and detailed chart documentation describes the adverse event, including its date and time, severity, generic medication dosage and duration of treatment, required intervention (if any), and relevant tests or laboratory data (if any).
      • A MedWatch form documents the generic medication trial and failure, including the adverse reaction.

    The entire oncology regimen will be covered when all drugs within the regimen are prescribed in accordance with the guidelines in this policy, provided the member has no exclusions to the prescribed therapy. Precertification is required for one or more agents within a prescribed oncology regimen. This policy applies to drugs covered under the pharmacy benefit listed in the Appendix; medical injectable and infusible drugs will also be reviewed when prescribed as part of the oncology regimen.

    This Drug Policy is intended to provide a guide to coverage and does not dictate how providers practice medicine. It does not discourage or prohibit other medical advice or treatment deemed appropriate by the treating physician.

    Benefit determinations are subject to applicable member contract language. If these guidelines conflict with the contract language, the contract language controls.

    This Drug Policy was developed through consideration of the medical necessity criteria under Hawaii's Patients' Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), generally accepted standards of medical practice, medical literature, and government approval status. HMSA has determined that services not covered under this Drug Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA or HMSA's Pharmacy Benefit Manager's medical-necessity determination in a given case, the physician may request reconsideration of the medical-necessity criteria as applied to the case with supporting documentation.

    Provider Requirements and Denial Risks

    Prior Authorization

    Oncology Regimen Precertification Required

    Precertification is required for applicable pharmacy-benefit oncology agents and for medical injectable or infusible drugs prescribed as part of an oncology regimen. The entire regimen is covered only when each drug follows this policy and the member has no applicable exclusions.

    • Review the Appendix to identify drugs requiring precertification from HMSA's Pharmacy Benefit Manager.
    • Submit the regimen for review before treatment or access when precertification is required.
    Step Therapy

    Generic-First Brand Exception

    Where applicable, the member must try and fail an A-rated generic equivalent before the corresponding brand medication can be approved. Brand access requires an intolerable adverse event from the generic that is not an expected active-ingredient adverse reaction and that is documented in the member's chart.

    • The generic trial-and-failure requirement applies before approval of the applicable brand product.

    Policy Scope

    This policy applies to oncology treatment delivered as a single agent or regimen, including pharmacy-benefit drugs listed in the Appendix and medical injectable or infusible drugs reviewed as part of the regimen. The entire regimen may be covered when each drug is prescribed in accordance with the policy and the member has no applicable exclusion.

    Initial authorization may be granted for 6 months when the treatment is supported by an FDA-approved indication or an NCCN category I or IIA recommendation. Continued authorization may be granted for an additional 12 months when current oncology documentation and objective measures demonstrate treatment benefit and no progression of disease.

    Initial Therapy Criteria

    Initial Authorization

    Authorization of 6 months may be granted for a single agent or regimen supported by one of the following.

    ONE of

    • FDA-approved indication: The therapy is prescribed for an FDA-approved indication.
    • NCCN recommendation: The therapy is supported by a National Comprehensive Cancer Network (NCCN) category I or IIA recommendation.NCCN I or IIA

    Continuation and Reauthorization Criteria

    Reauthorization

    Additional 12-month approval may be granted after prior HMSA or Pharmacy Benefit Manager approval when the following documentation demonstrates benefit.

    ALL of the following

    • Current oncology note: A current oncology note documents the patient's response to treatment and shows no progression of disease.No progression of disease
    • Current objective measures: Current imaging studies and other objective measures show no progression of disease compared with previous results.No progression compared with previous results

    Generic-First Requirement

    StepRequirementBrand exception criteria
    1Try and fail an A-rated generic equivalent before receiving an applicable brand medication.Failure must result from an intolerable adverse event that is not an expected reaction attributable to the active ingredient, and the event must be documented in the member’s chart.

    Dosing Limits for Covered Oncology Agents

    Quantity Limits
    Covered agentsOncology agents covered under this policy
    Dosing limitsApprovals may be subject to dosing limits
    Dosing standardFDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyPharmacy Global Oncology
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJul 23, 2026
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain precertification for one or more agents in every prescribed oncology regimen before treatment.
    SourceLink
    On This Page
    Coverage CriteriaProvider Requirements and Denial RisksPolicy ScopeInitial Therapy CriteriaContinuation and Reauthorization CriteriaGeneric-First RequirementDosing Limits for Covered Oncology Agents

    Unsupported block type: documentation

    Documentation Required

    Continuation Response Documentation

    For continuation or reauthorization, submit current oncology documentation and objective evidence showing benefit from treatment and no disease progression compared with prior results.

    • Current oncology note documenting response to treatment.
    • Current imaging studies and other objective measures; include pertinent laboratory tests, pathology reports, or imaging when relevant.
    Documentation Required

    Brand Exception Documentation

    When requesting brand approval after generic failure, provide detailed evidence of the adverse event and the generic trial. A MedWatch form documenting the trial, failure, and adverse reaction may be submitted instead.

    • Document the adverse event's description, date and time, severity, generic dosage and treatment duration, required intervention, and relevant tests or laboratory data, if any.
    Denial Risk

    Failure to Meet Authorization Criteria

    Authorization may be denied when required precertification is not obtained, clinical documentation does not support the diagnosis or treatment response, or the requested single agent or regimen does not meet the policy's authorization criteria. Members without a previous authorization—including new members and members already receiving treatment without prior authorization—must satisfy the initial-approval criteria.

    • The regimen must be supported by an FDA-approved indication or an NCCN category 1 or 2A recommendation.
    • Applicable generic-first and brand-exception requirements must be met.
    Denial Risk

    Progression or Lack of Documented Benefit

    Reauthorization may be denied when current documentation does not demonstrate treatment benefit or shows progression of disease. Additional authorization requires evidence supporting continued response and no progression.

    • Submit a current oncology note and current imaging or other objective measures for comparison with previous results.
    • The initial authorization period is generally 6 months; an approved reauthorization may extend coverage for an additional 12 months.
    Denial Risk

    FDA Label Difference Alone Is Insufficient

    Differences in FDA-labeled indications between a brand and its generic product are not, by themselves, sufficient to approve the brand over the generic because the products contain identical active ingredients and have proven bioequivalent pharmacokinetics.

    • A brand exception must be supported by the required generic failure and adverse-event documentation.
    Billing Rule

    Dosing Limits Apply

    Approval may be subject to dosing limits consistent with FDA-approved labeling, accepted compendia, and evidence-based practice guidelines.

    • Verify the requested dose and administration schedule against applicable labeling, compendia, and evidence-based oncology guidance.